<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816776</url>
  </required_header>
  <id_info>
    <org_study_id>Respicardia CR-1005</org_study_id>
    <nct_id>NCT01816776</nct_id>
  </id_info>
  <brief_title>Respicardia, Inc. Pivotal Trial of the remedē System</brief_title>
  <official_title>A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respicardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respicardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this prospective, multicenter, randomized trial is to evaluate the
      safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate
      to severe central sleep apnea and optimal medical management, compared to outcomes in
      randomized control subjects receiving optimal medical management and implanted but inactive
      remedē® systems.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">September 10, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Related Serious Adverse Events Within 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Apnea Index (CAI) Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Index (ArI) Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects with a &quot;moderate&quot; or &quot;marked&quot; improvement in the Patient Global Assessment from baseline to the 6 month visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops ≥4%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Sleep Apnea, Central</condition>
  <condition>Sleep Disordered Breathing</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment Group (transvenous stimulation of the phrenic nerve)</intervention_name>
    <description>device implant, optimal medical therapy and device initiation 1 month post implant.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>remedē System</other_name>
    <other_name>Transvenous stimulation of the phrenic nerve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Group (Optimal Medical Therapy)</intervention_name>
    <description>device implant, optimal medical therapy and delayed device initiation (7 months post device implant)</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Optimal Medical Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of
             scheduled implant:

               -  Apnea/Hypopnea Index (AHI) greater than or equal to 20;

               -  Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central
                  apnea events;

               -  Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI

          3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no
             hospitalizations for illness, no breathing mask-based therapy, and on stable
             medications and therapies:

               -  Stable medications are defined as no changes during this period except for those
                  within a pre-specified sliding scale medication regimen;

               -  If the subject has heart failure, the baseline testing (including PSG) should
                  occur at least 6 months after initial diagnosis;

               -  If the subject has systolic heart failure, the baseline testing (including PSG)
                  should occur after maximally titrating beta blockers, angiotensin converting
                  enzyme inhibitors (ACE-I) and other medications indicated in the current
                  guidelines (unless contraindicated or not considered medically necessary) and
                  after receiving any indicated device therapy including devices for cardiac
                  resynchronization therapy and/or primary prevention of sudden cardiac death;

               -  If subject has a hospitalization or physician visit requiring IV medication
                  between the screening PSG and implant, the subject must be re-screened when
                  stable

          4. Expected to tolerate study procedures in the opinion of the investigator, in
             particular:

               -  Ability to lie down long enough to insert the remede system without shortness of
                  breath and able to tolerate instrumentation for the Polysomnogram/Polygram
                  testing;

               -  Expected to tolerate therapy titration and the sensation of therapy, and
                  communicate therapy experience.

          5. In the investigator's opinion, willing and able to comply with all study requirements

          6. Signed the Institutional Review Board/Medical Ethics Committee approved informed
             consent (HIPAA authorization in the U.S.)

        Exclusion Criteria:

          1. Pacemaker dependent subjects without any physiologic escape rhythm

          2. Suspected inability to place catheter for delivery of stimulation lead (e.g.
             previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.)

          3. Evidence of phrenic nerve palsy

          4. More than 2 previous open chest surgical procedures (e.g., CABG)

          5. Etiology of central sleep apnea known to be caused primarily by pain medication

          6. Documented history of psychosis or severe bipolar disorder

          7. Cerebrovascular accident (CVA) within 12 months of baseline testing

          8. History of idiopathic pulmonary hypertension, World Health Organization Class 1

          9. Limited pulmonary function with either forced expiratory volume (FEV) 1/forced vital
             capacity (FVC) less than 65% of predicted value or FVC less than 60% of predicted
             value

         10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes
             of quiet rest

         11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6
             months post therapy initiation visit

         12. Active infection or sepsis within 30 days of enrollment

         13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated
             creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault
             equation

         14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase
             (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab
             normals at each site)

         15. Hemoglobin less than 8 gm/dL

         16. In subjects with heart failure, American College of Cardiology (ACC)/American Heart
             Association Heart (AHA) Stage D

         17. Within the 3 months prior to baseline testing, any of the following: uncorrected
             severe valvular stenosis, valve replacement or repair (percutaneous or surgical),
             myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery,
             percutaneous coronary intervention (PCI), cardiac ablation, new cardiac
             resynchronization device or new pacemaker implant

         18. New implantable cardioverter defibrillator or any implantable device generator
             change-out within 30 days prior to baseline testing or anticipated within the first 6
             months of enrollment

         19. Other anticipated surgery or invasive procedure expected to affect ability to perform
             testing at 6-month post-therapy initiation visit

         20. Unstable angina

         21. Allergy to or intolerant of contrast dye

         22. Pregnancy or of child bearing potential without a negative pregnancy test within 10
             days prior to remede system implant

         23. Life expectancy or expected time to transplant or left ventricular assist device of
             less than 12 months

         24. Currently enrolled or planning to enroll in another study that may conflict with
             protocol requirements or confound subject results in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosa Costanzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Heart Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Medical Group</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hospital-Advocate Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular (Allina)</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health System</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Medical Group, Inc. Presbyterian Sleep Health Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center - Novant</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bad Oeynhausen- Heart &amp; Diabetes Center</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Medical School, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernau-Herzzentruym Brandenburg</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bielefeld-Klinikun</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg: Universitares Herzzentrum</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulantes Herzzentrum-Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fourth Military Hospital</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <results_first_submitted>June 13, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Primary Effectiveness Assessed</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12"/>
                    <measurement group_id="B2" value="65" spread="13"/>
                    <measurement group_id="B3" value="65" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apnea-Hypopnea Index (AHI)</title>
          <description>The number of apneas and hypopneas per hour of sleep.
An apnea is defined by 3 characteristics:
There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by &gt; 90% of baseline
The duration of the event lasts at least 10 seconds
At least 90% of the event’s duration meets the amplitude reduction criteria for apnea
Hypopnea defined as 30% reduction in airflow (or alternative hypopnea sensor) for ≥10 seconds over at least 90% of the event’s duration that is associated with a &gt;4% fall in oxygen saturation from baseline.</description>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="19.3"/>
                    <measurement group_id="B2" value="43.7" spread="16.8"/>
                    <measurement group_id="B3" value="46.2" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Apnea Index (CAI)</title>
          <description>The number of central apneas per hour of sleep. A central apnea is defined by 4 characteristics:
There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by &gt; 90% of baseline
The duration of the event lasts at least 10 seconds
At least 90% of the event’s duration meets the amplitude reduction criteria for apnea
An apnea associated with absent inspiratory effort throughout the period</description>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="18.0"/>
                    <measurement group_id="B2" value="26.6" spread="16.1"/>
                    <measurement group_id="B3" value="28.2" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arousal Index (ArI)</title>
          <description>The number of arousals per hour of sleep. During sleep stages N1, N2, N3 or rapid eye movement (REM), an abrupt shift of electroencephalogram frequency including alpha, theta and/or frequencies greater than 16 Hz that last at least 3 seconds, with at least 10 seconds of stable sleep preceding the change is an arousal.</description>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="17.9"/>
                    <measurement group_id="B2" value="43.6" spread="19.1"/>
                    <measurement group_id="B3" value="44.6" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rapid Eye Movement Sleep (REM)</title>
          <description>REM is a sleep stage. The percentage of sleep in REM is a measure of sleep quality.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="7.2"/>
                    <measurement group_id="B2" value="11.8" spread="7.1"/>
                    <measurement group_id="B3" value="11.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oxygen Desaturation Index (ODI4)</title>
          <description>Number of times per hour of sleep that the blood's oxygen level drops by ≥4%.</description>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="21.7"/>
                    <measurement group_id="B2" value="37.5" spread="17.5"/>
                    <measurement group_id="B3" value="40.2" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obstructive Apnea Index</title>
          <description>The number of obstructive apneas per hour of sleep. An obstructive apnea is defined by 4 characteristics:
There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by &gt; 90% of baseline
The duration of the event lasts at least 10 seconds
At least 90% of the event’s duration meets the amplitude reduction criteria for apnea
An apnea associated with continued or increased inspiratory effort throughout the period</description>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="3.2"/>
                    <measurement group_id="B2" value="2.3" spread="2.7"/>
                    <measurement group_id="B3" value="2.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epworth Sleepiness Scale (ESS)</title>
          <description>The ESS is an assessment to measure a subject’s general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="5.2"/>
                    <measurement group_id="B2" value="9.5" spread="5.8"/>
                    <measurement group_id="B3" value="9.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="5.3"/>
                    <measurement group_id="B2" value="31.3" spread="6.6"/>
                    <measurement group_id="B3" value="31.1" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart failure</title>
          <description>Defined as New York Heart Association (NYHA) Functional Class ≥ I</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular ejection fraction</title>
          <description>Available for N=71 Treatment and N=75 Control participants.</description>
          <population>Ejection fraction data not available on all subjects</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71"/>
                    <count group_id="B2" value="75"/>
                    <count group_id="B3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="12.1"/>
                    <measurement group_id="B2" value="39.4" spread="12.2"/>
                    <measurement group_id="B3" value="39.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary artery disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant implantable device delivering therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI)</title>
        <description>Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group.</description>
        <time_frame>6 months</time_frame>
        <population>The population analyzed included all randomized participants who had a 6 month assessment. In addition, Treatment group subjects who did not have a 6 month assessment for reasons related to implant, device or delivered therapy were included as not achieving the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI)</title>
          <description>Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group.</description>
          <population>The population analyzed included all randomized participants who had a 6 month assessment. In addition, Treatment group subjects who did not have a 6 month assessment for reasons related to implant, device or delivered therapy were included as not achieving the endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided. p&lt;0.025 considered significant.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25</ci_lower_limit>
            <ci_upper_limit>54</ci_upper_limit>
            <estimate_desc>Risk difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Related Serious Adverse Events Within 12 Months</title>
        <description>Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat. The study protocol pre-specified that randomized groups be combined to assess freedom from related serious adverse events within 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Group</title>
            <description>All randomized participants pooled. All subjects were implanted with the remedē System device and received optimal medical therapy. The Treatment group had received 12 months active therapy and Control had received 6 months active therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Related Serious Adverse Events Within 12 Months</title>
          <description>Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit.</description>
          <population>Intent-to-treat. The study protocol pre-specified that randomized groups be combined to assess freedom from related serious adverse events within 12 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Apnea Index (CAI) Change From Baseline at 6 Months</title>
        <description>Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month polysomnogram (PSG) results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Central Apnea Index (CAI) Change From Baseline at 6 Months</title>
          <description>Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month polysomnogram (PSG) results or had unsuccessful implant attempt.</population>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" lower_limit="-30.5" upper_limit="-21.0"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-7.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided. Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.0</ci_lower_limit>
            <ci_upper_limit>-16.6</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months</title>
        <description>Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months</title>
          <description>Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" lower_limit="-28.8" upper_limit="-19.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-3.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-25.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.2</ci_lower_limit>
            <ci_upper_limit>-18.7</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arousal Index (ArI) Change From Baseline at 6 Months</title>
        <description>Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Index (ArI) Change From Baseline at 6 Months</title>
          <description>Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.2" lower_limit="-25.2" upper_limit="-15.2"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-9.2" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.6</ci_lower_limit>
            <ci_upper_limit>-8.7</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months</title>
        <description>Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months</title>
          <description>Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
          <units>percentage of sleep</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-0.3" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-2.4" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0244</p_value>
            <p_value_desc>1-sided. Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months</title>
        <description>The proportion of subjects with a &quot;moderate&quot; or &quot;marked&quot; improvement in the Patient Global Assessment from baseline to the 6 month visit</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt. Note: 1 Control subject did not provide a response and is excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months</title>
          <description>The proportion of subjects with a &quot;moderate&quot; or &quot;marked&quot; improvement in the Patient Global Assessment from baseline to the 6 month visit</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt. Note: 1 Control subject did not provide a response and is excluded from analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided. Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40</ci_lower_limit>
            <ci_upper_limit>68</ci_upper_limit>
            <estimate_desc>Risk difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months</title>
        <description>Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops ≥4%.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months</title>
          <description>Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops ≥4%.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
          <units>Events/hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" lower_limit="-23.9" upper_limit="-14.3"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-0.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.9</ci_lower_limit>
            <ci_upper_limit>-16.5</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months</title>
        <description>Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy and remedē System therapy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects implanted with the remedē System device who receive optimal medical therapy alone (remedē System inactive through 6 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months</title>
          <description>Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.</description>
          <population>Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to &quot;off&quot; at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-5.1" upper_limit="-2.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided. Secondary endpoints hierarchically tested with p&lt;0.025 considered significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
            <estimate_desc>Mean difference = Treatment – Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Implant through 12 Months post therapy initiation visit window</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pooled Group</title>
          <description>The study protocol pre-specified that randomized groups be combined to assess safety. All subjects were implanted with the remedē System device and received optimal medical therapy. The Treatment group had received 12 months active therapy and Control had received 6 months active therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Modified CTCAE v4.03</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HEART FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SUSTAINED VENTRICULAR TACHY ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CHEST PAIN - CARDIAC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF HEART FAILURE THERAPY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF CARDIAC SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE ICD SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RIGHT HEART PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DIABETIC TOE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>COLONIC PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL BLEED SECONDARY TO WARFARIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GASTROPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PERFORATED BOWEL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>IMPENDING POCKET EROSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>STIMULATION LEAD DISLODGEMENT (REMEDE SYSTEM)</sub_title>
                <description>The stimulation lead pulled out of the target vessel and required the lead to be replaced in order to deliver therapy</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ALTERED MENTAL STATUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CONCOMITANT DEVICE INTERACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DEGENERATIVE JOINT DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ELECTIVE EXPLANT OF REMEDE SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>EXTRA-RESPIRATORY STIMULATION</sub_title>
                <description>Discomfort of feeling delivered therapy in areas remote from the diaphragm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>FLU LIKE SYMPTOMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ICD LEAD FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE HEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SINUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>STIMULATION LEAD COMPONENT FAILURE (REMEDE SYSTEM)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>STIMULATION LEAD DISPLACEMENT (REMEDE SYSTEM)</sub_title>
                <description>The stimulation lead remained in the target vessel but electrode position did not allow for effective therapy delivery</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BLADDER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BRONCHIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ICD IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LEG CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>AORTIC INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>INTRAOPERATIVE NEUROLOGICAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELEVATED TRANSAMINASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BICEP TENDON TEAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MENISCUS TEAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PROSTATE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>STROKE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHEMIC ATTACKS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>URINARY TRACT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PULMONARY EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CRT-D IMPLANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CYCLOPHOTOCOAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DRUG ELUTING STENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ICD GENERATOR AND RV LEAD REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ICD IMPLANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LEFT SUBTALAR JOINT ARTHRODESIS, HARDWARE REMOVAL AND BONE GRAFTING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>TOOTH EXTRACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Modified CTCAE v4.03</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DIAPHRAGMATIC STIMULATION DISCOMFORT</sub_title>
                <description>Discomfort in the abdominal area due to remede System delivered therapy</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>EXTRA-RESPIRATORY STIMULATION</sub_title>
                <description>Discomfort of feeling delivered therapy in areas remote from the diaphragm</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Nelson, VP Clinical Affairs</name_or_title>
      <organization>Respicardia, Inc.</organization>
      <phone>952-540-4479</phone>
      <email>lnelson@respicardia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

